Elevation Pharmaceuticals has announced that a Phase 2b study of its EP-101 glycopyrrolate inhalation solution in patients with moderate to severe COPD demonstrated that EP-101 produced statistically significant improvement in lung function compared to placebo after 7 days. The GOLDEN-1 (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) study … [Read more...] about Positive Phase 2b results for Elevation’s glycopyrrolate inhalation solution
News
Insmed appoints Donald J. Hayden, Jr. as Executive Chairman of the Board of Directors
Insmed Incorporated, which is developing Arikace liposomal amikacin for inhalation, has appointed Donald J. Hayden, Jr. as Executive Chairman of its Board of Directors, effective immediately. He has been serving as Chairman of the board of directors since the end of 2010 when Insmed merged with Transave, and he will continue to focus on the development of Arikace … [Read more...] about Insmed appoints Donald J. Hayden, Jr. as Executive Chairman of the Board of Directors
CDC survey shows that almost 19 million US adults have asthma
Data from the Centers for Disease Control and Prevention (CDC) Asthma Call-back Survey show that 18.7 million US adults (8.2 percent) have asthma today out of approximately 29.1 million adults (12.7 percent) who have been diagnosed with asthma at some point in their lifetimes. The data are contained in a report called Asthma’s Impact on the Nation. According to the … [Read more...] about CDC survey shows that almost 19 million US adults have asthma
Pulmatrix touts iSPERSE potential for inhaled therapies
Pulmatrix is presenting two posters at RDD, one titled “Formulation Characterization of a Novel Levofloxacin Pulmonary Dry Powder Drug Delivery Technology,” and the other titled “Development of an iSPERSE Based Platform for the Delivery of Macromolecules via Dry Powder Formulations.” The posters include data from in vitro and preclinical studies of formulations … [Read more...] about Pulmatrix touts iSPERSE potential for inhaled therapies
Study confirms ergonomic advantages of Aptar inhaler
Aptar Pharma is presenting results from a clinical study of patient ability to use its Prohaler DPI at RDD this week. The study, which was conducted by Professor Patrice Diot at the Centre Hospitalier Regional Universitaire (CHRU) in Tours, France, demonstrated that all of the asthma and COPD patients involved in the study, no matter how ill, were able to trigger the … [Read more...] about Study confirms ergonomic advantages of Aptar inhaler
Liquidia publishes data from studies of inhalation formulations created with its particle engineering technology
Liquidia Technologies has announced results from two studies of inhalation formulations created using the company’s PRINT (Particle Replication In Non-Wetting Templates) particle engineering technology. One study, published in the 2012 issue of the Journal of Drug Delivery, compared aerodynamic properties of PRINT-zanamivir inhalation powder to Relenza; the other, … [Read more...] about Liquidia publishes data from studies of inhalation formulations created with its particle engineering technology
Pearl reports new data from studies of PT003
Pearl Therapeutics is presenting data from studies of its PT003 metered dose inhaler, glycopyrrolate (GP)/formoterol fumarate (FF) fixed dose combination for the treatment of moderate-to-severe COPD at a number of upcoming meetings. Pearl is also developing MDIs with each of the two component drugs, PT001 (GP) and PT005 (FF). According to the company, one of the … [Read more...] about Pearl reports new data from studies of PT003
Copley Scientific establishes distributors in Turkey, Brazil, and China
Inhaler testing equipment company Copley Scientific has entered into distribution agreements with companies in Turkey and Brazil and now has a Chinese sales and technical support representative in Nanjing, China. Copley sells a range of inhaler testing products, including impactors, delivered dose sampling apparatus, breath simulators, and proprietary inhaler testing … [Read more...] about Copley Scientific establishes distributors in Turkey, Brazil, and China
Pulmotect gets $7.1 million for inhaled immune system stimulant
Texas-based biotechnology company Pulmotect has been granted an award of $7.1 million by the Cancer Prevention & Research Institute of Texas (CPRIT) for development of its lead product PUL-042, an inhaled immune stimulant composed of two synthetic toll-like receptor agonists. The award is intended to fund preclinical, Phase 1, and Phase 2 studies of the product for … [Read more...] about Pulmotect gets $7.1 million for inhaled immune system stimulant
Study shows equivalent safety for Symbicort compared to budesonide alone in African Americans
AstraZeneca has announced results of a study showing that the safety profile of Symbicort budesonide/formoterol inhalation aerosol 320/9 µg twice daily was similar to that for a budesonide alone pMDI 320 µg twice daily in African-American patients with moderate-to-severe asthma. The data from the 52-week randomized, double-blind Phase IIIb safety study were published … [Read more...] about Study shows equivalent safety for Symbicort compared to budesonide alone in African Americans